Search

News & Events

One of the researchers who helped crack the code of 10-year-old Northam girl Charlotte Patterson’s incredibly rare disease has received State Government funding that will allow her to use the same methods to rapidly assess the cases of hundreds more patients living with undiagnosed disease.

News & Events

Michelle Pianta knew deep down something was very wrong with her seven-and-a-half month old son Jackson as she waited at Bunbury Hospital for his blood results.

News & Events

Dr Rishi Kotecha knows too well the devastation of a leukaemia diagnosis in a child, treating children as a consultant at Princess Margaret Hospital.

News & Events

Four The Kids Research Institute Australia researchers are among those who have received funding in the WA State Government's Merit Award Program announced today.

News & Events

Researchers at The Kids Research Institute Australia have discovered a new drug combination that could help improve survival rates for babies with leukaemia.

News & Events

It is now known that the HOX11 gene is permanently activated in the leukaemia cells and it drives the disease.

News & Events

West Australian families are being asked to play a vital role in a major new national study to unravel the causes of childhood leukaemia.

Research

Monoclonal antibodies are revolutionizing the landscape of current cancer treatment, bringing hope to patients with incurable cancers. B7-H3 (CD276) is an attractive therapeutic target for antibody-based therapy due to its low or absent expression in normal tissues and high expression in various types of tumors, including prostate cancer, pancreatic cancer, and high-mortality esophageal squamous cell carcinoma (ESCC). In recent years, various B7-H3-targeting antibodies have been developed for cancer treatment, with a few making their way to clinical trials.

Research

T cells engineered to express chimeric antigen receptors (CARs) are a promising modality to treat refractory cancers. CD19 CAR-T therapy has achieved remarkable responses in against B-cell lymphomas, however, challenges persist for acute myeloid leukemia (AML) and solid malignancies. B7H3 is an immune regulatory molecule that is highly expressed in various tumor cells. Its abnormal expression in acute AML and esophageal squamous cell carcinoma (ESCC) is closely related to tumor progression. 

Research

OLIG2-expressing tumor stem cells have been shown to drive recurrence in Sonic Hedgehog (SHH)-subgroup medulloblastoma (MB) and patients urgently need specific therapies to target this tumor cell population.